Hydroxychloroquine Market , By Disease Indication (Malaria, Coronavirus Disease, Lupus Erythematosus, and Rheumatoid Arthritis), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), by and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jul 2023

Code : CMI3727

Pages :145

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Hydroxychloroquine Market : Key Developments

On May 2, 2023, Icannex Healthcare- medicinal cannabinoid and psychedelic therapy development company, started its Phase II trial of cannabidiol (CBD) and hydroxychloroquine combinational therapy in Rheumatoid Arthritis.

In November, 2020, Jubilant Pharma Limited- a manufacturer and supplier of radiopharmaceuticals and Aavis Pharmaceuticals Inc- a U.S based pharmaceutical company, announced the launch of Hydroxychloroquine tablets to counter Malaria , Rheumatoid Arthritis and Lupus in the U.S.

In April 2022, the Indian government lifted a ban on the export of hydroxychloroquine, paving the way for the anti-malaria drug to be shipped to the U.S. for use against the coronavirus.

In April 2020, Galenika- Serbia based pharmaceutical company and Zada Pharmaceuticals- a Bosnia based pharmaceutical company announced the launch of a production unit of chloroquine and hydroxychloroquine for the treatment of COVID-19 patients.